Atrium Therapeutics Launch / Spinout Capitalization

Date: 27-Feb-2026 | Size: Approximately US$270M | Therapeutic area: Cardiovascular / RNA medicines (rare genetic cardiomyopathies)

Investors: Not separately disclosed in the launch announcement; company launched with approximately US$270M in cash and cash equivalents

What they do: Precision cardiology company spun out in connection with Novartis’ acquisition of Avidity, developing targeted RNA medicines for rare genetic cardiomyopathies. Lead programs ATR 1072 and ATR 1086 target PRKAG2 syndrome and PLN cardiomyopathy, respectively, and are expected to enter the clinic over the next couple of years.

BreezeBio Series B

Date: 25-Feb-2026 | Size: US$60M | Therapeutic area: Genetic medicine / non-viral delivery (autoimmune disease, oncology)

Investors: Led by new investors Yuanta Investment and DSC Investment; participation from SV Investment, Kiwoom Investment, STIC Ventures, Top Harvest Capital; existing investors DAYLI Partners, Pathway Investment, Loftyrock Investment, Korea Investment Partners, WOORI Venture Partners, KDB Silicon Valley, and ACVC Partners also participated

What they do: Formerly GenEdit, BreezeBio is building precise non-viral genetic medicines using its NanoGalaxy platform. Lead program BRZ-101 is designed to restore immune tolerance in type 1 diabetes, with proceeds supporting internal pipeline advancement toward the clinic and continued platform expansion.

Slate Medicines Series A

Date: 24-Feb-2026 | Size: US$130M | Therapeutic area: Neurology / migraine and headache disorders

Investors: Co-led by RA Capital Management, Forbion, and Foresite Capital, with participation from an additional undisclosed biotech investor

What they do: Headache-focused biotech advancing next-generation anti-PACAP therapies. Lead asset SLTE-1009, licensed from DartsBio, is a potentially best-in-class anti-PACAP monoclonal antibody with half-life extension for subcutaneous dosing and is on track to enter Phase 1 in mid-2026.

Altesa BioSciences Series B

Date: 19-Feb-2026 | Size: US$75M | Therapeutic area: Respiratory / antivirals (COPD, chronic lung disease)

Investors: Led by Forbion, with participation from Sanofi and existing investors Medicxi, Pitango, and Atlantic Partners

What they do: Clinical-stage company focused on chronic lung disease. Proceeds support vapendavir, a first-in-class antiviral targeting rhinovirus—the leading cause of respiratory exacerbations in COPD and other chronic lung diseases—with initiation of the Phase 2b CARDINAL study planned for Q2 2026.

Korsana Biosciences Seed + Series A disclosed at launch

Date: 18-Feb-2026 | Size: US$175M total funding disclosed (US$25M seed in 2024 + US$150M Series A in Sept-2025) | Therapeutic area: Neurodegeneration / Alzheimer’s disease

Investors: Seed from Fairmount and Venrock Healthcare Capital Partners; Series A co-led by Wellington Management and TCGX, with participation from J.P. Morgan Life Sciences Private Capital, Janus Henderson Investors, Sanofi Ventures, Foresite Capital, and others

What they do: Neurodegeneration company advancing potential best-in-class therapies, initially focused on Alzheimer’s disease. Lead program KRSA-028 is designed to cross the blood-brain barrier via transferrin receptor binding to enable amyloid-targeted therapy in the CNS.

ILiAD Biotechnologies Series B

Date: 09-Feb-2026 | Size: US$115M | Therapeutic area: Infectious disease / vaccines (pertussis)

Investors: Led by RA Capital Management; participation from new investors Janus Henderson Investors and BNP Paribas Asset Management Alts; existing investors include a multi-national pharmaceutical company and AI Life Sciences

What they do: Advanced clinical-stage biotech focused on prevention/treatment of Bordetella pertussis. Lead candidate BPZE1 is a live attenuated intranasal pertussis vaccine designed to induce systemic + mucosal immunity; proceeds to support Phase 3 development with a pivotal human challenge trial expected to begin in 2026.

QuantX Biosciences Series B

Date: 09-Feb-2026 | Size: US$85M | Therapeutic area: Immunology & inflammation (oral small molecules)

Investors: Co-led by Lilly Asia Ventures (LAV) and Sanofi Ventures; additional investors included Hongshan; plus existing investors

What they do: Computationally driven drug discovery/development company using advanced modeling + high-performance computing to design and optimize oral small-molecule therapeutics. Proceeds to support clinical development of a best-in-class oral STAT6 inhibitor and an oral IL-17 inhibitor, plus continued discovery for oral I&I therapies.

Aerska Series A

Date: 09-Feb-2026 | Size: US$39M | Therapeutic area: CNS / neurology (RNA medicines; RNAi delivery)

Investors: Led by EQT Dementia Fund and age1, with participation from Iaso Ventures, alongside existing investors

What they do: Biotech developing RNA medicines for CNS diseases using proprietary “brain shuttle” technology to improve delivery of RNAi therapeutics across the blood-brain barrier. Proceeds support continued development of its antibody-oligo conjugate (AOC) platform as it progresses toward the clinic.

Galux Series B

Date: 09-Feb-2026 | Size: US$29M | Therapeutic area: AI-driven protein therapeutics / antibody design platform

Investors: Existing investors InterVest, DAYLI Partners, and PATHWAY Investment; new investors include Yuanta Investment, Korea Development Bank (KDB), SL Investment, NCORE Ventures, SneakPeek Investments, Korea Investment & Securities, and Mirae Asset Securities

What they do: South Korea-based biotech building an AI-driven protein design platform focused on de novo antibody design. Proceeds support platform R&D, pipeline development, and global expansion (including next-gen AI incorporating functional activity + developability).

Pandorum Technologies Series B

Date: 07-Feb-2026 | Size: US$18M | Therapeutic area: Regenerative medicine (exosome-based; ophthalmology-first)

Investors: Led by Protons Corporate; participation from Galentic Pharma, Ashish Kacholia, Noblevast Advisory, Avinya Fund, Burman Family, and others

What they do: Biotech developing disease-modifying, tunable, exosome-based regenerative therapies. Proceeds to advance clinical development (including Kuragenx) while scaling global manufacturing and expanding operations across the U.S., Japan, and the Middle East.

Angitia Biopharmaceuticals Series D

Date: 05-Feb-2026 | Size: US$130M | Therapeutic area: Musculoskeletal / Bone (osteoporosis, OI, spinal fusion)

Investors: Co-led by Frazier Life Sciences and Venrock Healthcare Capital Partners; new investors include Ascenta Capital, funds/accounts managed by BlackRock, BVF Partners, Logos Capital, RA Capital Management, Wellington Management; existing investors include Bain Capital Life Sciences, Elikon Venture, Janus Henderson Investors, 3H Health Investment, Hillhouse Investment, Legend Capital, Morningside Group, OrbiMed, TF Capital, Yonghua Capital

What they do: Clinical-stage biotech developing biologics aimed at improving musculoskeletal health; proceeds support clinical development of AGA2118, AGA2115, AGA111 and broader pipeline.

Third Arc Bio Series A Extension

Date: 04-Feb-2026 | Size: US$52M | Therapeutic area: Oncology + Immunology/Inflammation (multispecific antibodies)

Investors: Led by Andreessen Horowitz (a16z) with founding investor Omega Funds; additional investors include Life Sciences at Goldman Sachs Alternatives, BVF Partners, funds managed by abrdn, accounts advised by T. Rowe Price Associates, Marshall Wace, Hillhouse Investment, Galapagos, AbbVie Ventures, Alderline Group

What they do: Clinical-stage biotech developing multifunctional/multispecific antibodies across oncology and I&I; lead program ARC101 is a bispecific T-cell engager (CLDN6) in Phase 1; proceeds accelerate I&I portfolio and advance additional oncology programs into clinic.